Therapeutic antibody - Eli Lilly/MedarexAlternative Names: LLY Antibody
Latest Information Update: 24 Mar 2009
At a glance
- Originator Medarex
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 24 Mar 2009 Discontinued - Phase-I for Undefined indication in USA (unspecified route)
- 07 Apr 2006 This programme is still in active development
- 17 Sep 2004 Phase-I clinical trials in Undefined in USA (unspecified route)